CliffBio
small molecule

CARBIDOPA, LEVODOPA AND ENTACAPONE

CARBIDOPA; ENTACAPONE; LEVODOPA

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameCARBIDOPA, LEVODOPA AND ENTACAPONE
Active ingredientCARBIDOPA; ENTACAPONE; LEVODOPA
Strength37.5MG;200MG;150MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalFebruary 2026
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.